EUSA Pharma establishes subsidary in Korea

a UK-based specialty pharmaceutical company that focuses on rare and incurable diseases

Establishes the Asia Pacific headquarter and Korean branch …. appoints Yeon Jae Lee as General Manager

Owns Castleman Disease treatment ‘Sylvant’ among others…merged with Recordati

The UK-based pharmaceutical company EUSA Pharma is entering the Korean market.

 

According to industry sources, EUSA Pharma established the Asia Pacific Regional Headquarters in Korea and launched its Korean subsidiary, EUSA Pharma Korea.

 

EUSA Pharma is a global specialty pharmaceutical company that focuses on rare and incurable diseases that were established with funding support from a leading life science investor EW Healthcare Partners.

 

The company is currently a multinational pharmaceutical company that has branches in Europe, the Middle East, Africa, the United States, South America, the and Asia Pacific region, and recorded sales of 130 million euros as of June 2021.

 

Its leading product is ‘Sylvant (siltuximab),’ a Multicentric Castleman‘s Disease treatment that is being distributed by Janssen Korea in Korea.

 

Sylvant is being listed and prescribed with reimbursement from February 2018.

 

Also, Yeon Jae Lee was appointed General Manager of the Asia Pacific region and Korean subsidiary.

 

Lee is a seasoned professional in the pharmaceutical industry, who served in various posts at Novartis Korea, Daewoong Pharmaceuticals, and as the Country Head of UCB Korea and the Head of Rare Blood Disorders at Sanofi-Aventis Korea.

 

Meanwhile, the Italian pharmaceutical company Recordati confirmed the deal to acquire EUSA Pharma at the end of last year.

 

As the acquisition process is expected to be completed within the first half of this year, Whether EUSA Pharma will be maintained in its current form remains to be seen.